Iveric bio Inc.
IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.